The conceptual and clinical problems of paraneoplastic syndrome in oncology and internal medicine by Bilynsky, B.T. et al.
82 Experimental Oncology 37, 82–88, 2015 (June)
THE CONCEPTUAL AND CLINICAL PROBLEMS OF PARANEOPLASTIC 
SYNDROME IN ONCOLOGY AND INTERNAL MEDICINE
B.T. Bilynsky1,*, M.B. Dzhus2, R.I. Litvinyak3
1Danylo Halytsky Lviv National Medical University, Lviv 79010, Ukraine
2O.O. Bogomolets National Medical University, Kyiv 01601, Ukraine
3Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv 79031, Ukraine
Symptomatology of oncological diseases consists not only of local symptoms caused by the primary malignancy or its metastases, 
but also by general systemic signs that are not directly connected with the tumor. These symptoms are mostly associated with auto-
immunity or endocrine influences. In many cases, the source of paraneoplastic syndromes (PNS) is unknown. Nearly 15% of on-
cological patients demonstrate these syndromes but it is diagnosed much more rarely. The survey of the numerous PNS is offered. 
The significance of the PNS differs for oncologists and other physicians who encounter it in their practice. The reason of those 
differences, as well as the connection between PNS and cancer toxicity is discussed. The experience of antitoxic therapy (hemo-
sorption, lymphosorption, enterosorption) used in our clinic in the previous years is overviewed.
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Tumors usually produce symptoms by invasion, 
obstruction and bulk mass on the primary localization 
of neoplasm and their regional or distant metastases. 
In addition, tumors can produce signs at a distance 
from their localization. These are the so-called para-
neoplastic syndromes (PNS) [1, 2].
These syndromes are not a direct effect of the tu-
mor or its metastases. They are caused by substances 
produced by tumor and distributed by circulation. 
These substances act on the target organs and result 
in clinical picture named PNS. Most of these substan-
ces are polypeptide hormones, autoantibodies, growth 
factors, cytokines, hormones and their precursors. 
The ethiology and pathogenesis of a number of PNS 
are unknown till now (e.g. acanthosis nigricans) and 
require additional investigations [3].
Over the last years, many of these tumor-se-
creted proteins have been described. The PNS may 
be the first sign of a malignancy and we can use it for 
early cancer detection. PNS does not predict the result 
of treatment of the underlying malignancy [4].
Thus, proteins secreted in PNS may be used as tu-
mor markers. Different PNS caused by diverse reasons 
(hormonal, immunological etc.) demonstrate various 
treatment results. A successful treatment of the tumor 
usually leads to disappearance of the PNS. In many 
cases, the underlying tumor cannot be treated, but 
symptoms and complications of the PNS can be suc-
cessfully managed by nonspecific means which were 
tried in our institution (Lviv Oncological Center) several 
years ago [5]. 
It is believed that appearance of PNS is connected 
with endocrine, immunological or metabolic influ-
ences of the tumor. Over 600 PNS have already been 
described so far (Table).
Table1. Most common PNS
Syndrome 
group Clinical signs
Cutane-
ous
Acanthosis nigricans maligna
Erythema gyratum repens
Bazex paraneoplastic acrocheratosis
Acquired hypertrichosis lanuginose
Necrolytic migratory erythema
Leser-Trélat Sign
Paraneoplastic pemphigus
Dermatomyositis
Sweet syndrome
Palmoplantar keratoderma
Pyoderma gangrenosum
Neurolo-
gical
Limbic encephalitis
Subacute cerebellar degeneration
Opsoclonus-myoclonus
Optic neuritis
Cancer associated retinopathy
Subacute sensory neuronopathy
Guillain — Barre’ syndrome
Chronic gastrointestinal pseudo-obstruction
Myasthenia gravis
Lambert — Eaton myasthenic syndrome
Necrotising myelopathy
Endocrine SIADH
Hypercalcemia
Cushing syndrome
Hypoglycemia
Hemato-
logic
Eosinophilia
Granulocytosis
Pure red cell aplasia
Thrombocytosis
Thrombocytopenia
Anemia
Coagulopathies (thrombophlebitis, thromboembolism, disse-
minated intravascular coagulation — DIC)
Rheuma-
tologic
Paraneoplastic polyarthritis
Remitting seronegative symmetrical synovitis with pitting edema
Polymyalgia rheumatica
Palmar fasciitis
Multicentric reticulohistiocytosis
Tumor-induced osteomalacia
Vasculitis
Renal Glomerulonephritis
Nephrotic syndrome
Submitted: March 5, 2015.
*Correspondence:  E-mail: litrus@ukr.net
Abbreviations used: aPL — antiphospholipid antibodies; CLL — 
chronic lymphocytic leukemia; DIC — disseminated intravascular 
coagulation; PNS — paraneoplastic syndromes.
Exp Oncol 2015
37, 2, 82–88
REVIEWS
Experimental Oncology 37, 82–88, 2015 (June) 83
Syndrome 
group Clinical signs
Others Cachexia
Fatigue
Fever
Lactic acidosis
Hypouricemia
Their number is constantly increasing, but 
it is disputable whether all of them can be evaluated 
as PNS. True PNS satisfy two main criteria: strong as-
sociation of suspected PNS with malignancy and their 
parallel course [3].
PARANEOPLASTIC CUTANEOUS 
SYNDROMES
For clinicians these syndromes can be of diagnostic 
value. The attitude of different medical experts to this 
phenomenon differs: dermatologists observe PNS 
or similar syndromes in skin diseases. Most important 
for is to establish a differential diagnosis between der-
mal PNS and plural dermatosis. Cutaneous manifesta-
tions of distant cancer are more frequent than other 
similar appearances, and an especially wide variety 
of skin syndromes is associated with malignancies [6]. 
These are first of all keratinization disorders. The most 
important PNS of this kind is acanthosis nigricans. 
It is characterized by grey-brown hyperpigmented 
velvety plaques that often affect the neck, flexor are-
as, and anogenital region. It is typically associated 
with ade nocarcinomas of the gastrointestinal tract, 
predominantly with gastric cancer, but can be as-
sociated with other adenocarcinomas (lung, breast, 
ovarian, and even hematologic malignancies) [7]. 
In addition, keratinization disorders are represented 
by tripe palms, usually associated with lung or gastric 
cancers, acquired ichtiosis (associated with Hodg-
kin’s and ot her lymphomas, multiple myeloma, Ka-
posi’s sarcoma). Palmar hyperkeratosis is associated 
with esophageal, breast, and ovarian carcinomas [8].
It is relevant to name several other cutaneous 
PNS connected with different tumors: acrokeratosis 
paraneoplastica (Bazex’ syndrome), associated with 
squamous cell carcinoma of the esophagus, head and 
neck or lung tumors. It precedes the tumor in 60% 
of cases. Exfoliative dermatitis may be associated 
with lymphomas and rarely with solid tumors (lung, 
liver, prostate) [9].
Disorders of cutaneous discolonation and de-
positation (melanosis, plain xantomas, vitiligo, and 
leucoderma) are also considered to be PNS associated 
with different malignancies. Neuroplastic dermatoses 
constitute an interesting group. Sweet’s syndrome 
presents with acute onset: fever, neutrophilia and 
appearance of cutaneous plaques on the face, neck, 
and upper extremities. Association with malignancies 
occurs in 20% of cases. The other dermatologic PNS 
is pyroderma gangrenous appears as a form nonhea-
ling ulcers with a necrotic base.
Pyoderma gangrenosum is associated with he-
matological malignancies, inlcluding cutaneous 
T-cell lymphomas, gastric carcinomas, and other 
gastrointestinal abnormalities. I (here — B. Bilyn-
sky) remember a clinical case when during a clinical 
patient round I, being a young docent, diagnosed 
gastric cancer due to the presence of black spots 
on the patient’s face (acanthosis nigricans), which 
was evaluated by my colleagues as melanoma [8, 10].
Vascular abnormalities belong to dermatological 
appearances. Episodic reddening of the face and neck 
lasting a few minutes is associated with the carcinoid 
syndrome, leukemia, medullary carcinoma of the thy-
roid, renal cell carcinoma, systemic mastocytosis, and 
pheochromocytoma. Multifocal migratory thrombo-
phlebitis (antiphospholipid syndrome) is associated 
with numerous malignancies, most commonly with 
gastrointestinal, but also lung, prostate, ovary tumors, 
leukemias and lymphomas. It is related to hyperco-
agulable state accompanying the advanced cancer. 
A cordlike thrombophlebitis on the thoracic wall 
(Mondor’s disease) may be associated with breast 
cancer. Pruritus may be the initial feature of an occult 
malignancy or a clinical manifestation of a previously 
diagnosed tumor. There are other numerous additional 
hereditary disorders associated with cutaneous mani-
festations of malignancy [3, 6].
Dermatologic PNS include also a number of en-
docrine and metabolic lesions (systematic modular 
panniculitis or subcutaneous fat necrosis, hyperpig-
mentation by Addison syndrome), telangiectasia, and 
scleroderma-like changes in carcinoid syndrome, and 
others [7, 8].
Bullous disorders, mostly paraneoplastic pemphi-
gus usually occur in the presence of B-cell lympho-
proliferative disorders — lymphomas, chronic lympho-
cytic leukemia (CLL), Castleman’s disease, thymoma, 
Waldenstöm’s macroglobulinemia, and spindle cell 
neoplasms. Dermatologic PNS can be represented 
by colagen-vascular diseases, disorders of hair, and 
some skin neoplasms associated with internal malig-
nancy. To the latter belong such autosomal-dominant 
syndromes as Muir — Torre syndrome (numerous 
sebaceous gland neoplasms), Cowden’s syndrome 
(multiple hamartomas), Gardner’s syndrome (hun-
dreds of adenomatous colorectal polyps and nume-
rous epidermal cysts and soft tissue tumors), and 
Gorlin-Goltz syndrome (multiple basal cell carcinomas 
with numerous bony abnormalities and a strong pre-
disposition for malignancy) [3, 9, 10].
PARANEOPLASTIC NEUROLOGICAL 
SYNDROMES
Neurologic manifestations of PNS are close 
to the dermatologic ones, and often have some com-
mon signs and etiological display with the skin syn-
dromes [11].
Neurological symptoms that are not related 
to the direct effect of malignancies on the neurologic 
system are defined as PNS. These syndromes include 
dermatomyositis, Lambert — Eaton myasthenic syn-
drome, subacute cerebellar degeneration, subacute 
sensory neuropathy, opsoclonus-myoclonus, sensory 
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motor peripheral neuropathy, encephalomyelitis, and 
many others [11, 15]. Such neurologic disorders 
as PNS are associated with different malignancies 
in 10–60% of cases. Paraneoplastic disorders are 
also a rare cause in vision loss in cancer patients [12].
A number of antineural antibodies appear in the case 
of PNS and cancers. That is why neurologists have 
to be interested in recognition of the PNS, which would 
lead to the correct determination of diagnosis and ap-
plication of an adequate treatment [12, 27].
PARANEOPLASTIC ENDOCRINE 
SYNDROMES
Once a PNS is diagnosed, an appropriate systemic 
evaluation for a neoplasm is to be undertaken. The ma-
jority of PNS are connected with endocrinological 
disorders. In their practice, the experts in endocrino-
logy encounter such clinical cases that are frequently 
associated with a wide variety of common cancers.
A number of PNS are associated with secretion 
of several hormones and hormone-like substances. 
The most widespread of them are ACTH (Cushing 
syndrome), antidiuretic hormone, insulin-like growth 
factor, erythropoietin, growth factor realizing hormone, 
parathormone-like protein, etc. [13, 28].
The following tumors are associated with ectopic 
adrenocorticotropic hormone: small cell lung carci-
noma, bronchial carcinoid, thymic carcinomas, tumors 
of pancreas, pheochromocytoma, medullary cancer 
of the thyroid, gastrointestinal carcinoid, adenocarci-
noma, etc. [13, 14].
Clinical features of inappropriate antidiuretic hor-
mone production syndrome consist of combination 
of water retention and secondary solute loss which 
leads to the fall of plasma sodium concentration. 
As a rule, the patients have normal volume status, 
hypothermia with hypoosmolality, elevated renal ex-
cretion of sodium, and urine osmolality greater than 
plasma osmolality. Most common clinical symptoms 
in these patients are caused by central nervous sys-
tem toxicity. Patients complain of fatigue, anorexia, 
headaches, and altered mental status. Further, with 
the progress of the syndrome the delirium, confu-
sion, and seizures develop. The syndrome may cause 
a coma, and in rare cases result in death. Most patients 
have minimal symptoms and during routine laboratory 
evaluation are diagnosed with hyponatremia [2, 11, 19].
Tumors associated with bone metastases (breast, 
prostate, lung cancers) lead to hypocalcemia. Those 
patients have increased skeletal avidity for calcium. 
Hypocalcemia can also occur in patients, whose tu-
mors secrete calcitonin (medullary thyroid carcinoma, 
breast cancer, colorectal cancer, lung cancer, carci-
noid). Hypocalcemia has many clinical manifestations. 
It can be asymptomatic, in some cases it demonstrates 
significant symptoms associated with neuromuscular 
irritability and cardiovascular changes: peripheral and 
perioral paresthesia, cramps, tetany, seizures, bron-
chospasm, laryngospasm, anxiety, confusion, cardiac 
arrhythmias, and congestive cardic failure. In extreme 
cases hypocalcemia is life threatening, especially if not 
recognized and untreated [3, 16, 17].
Tumor induced osteomalatia is a rare PNS charac-
terized by hypophosphatemia and very low circulating 
concentrations of vitamin D3. The majority of neo-
plasms causing this syndrome are benign, but this PNS 
can coexist with lung carcinoma, multiple myelomas, 
and prostate cancer. Patients present with bone pain, 
phosphaturia, renal glucosuria, hypophosphatemia, 
normocalcemia, low level of 1,25 dihydroxyvitamin D3, 
and increased alkaline phosphatase level [18].
Mesenchemal tumors and hepatic carcinomas are 
mostly responsible for hypoglycemia as a PNS. Insu-
lomas also frequently produce hypoglycemia. Gas-
trointestinal stromal tumors, lymphomas and adrenal 
carcinomas may also be associated with this PNS. Pa-
tients may have typical signs of hypoglycemia inclu-
ding generalized neurologic abnormalities. The causes 
of paraneoplastic hypoglycemia include production 
of nonsuppressible insulin-like GF-1 and GF-2, hy-
permetabolism of glucose, production of substances 
stimulating ectopic insulin release, production of he-
patic glucose inhibitor, insulin binding by a monoclonal 
protein, insulin receptor proliferation or — rarely — 
ectopic insulin production [4, 11].
We can make a conclusion that in many cases 
endocrinologists have common problems with on-
cologists and clinical errors may happen in some 
unexpected circumstances, when a PNS is evaluated 
as a hormonal disease.
PARANEOPLASTIC HEMATOLOGIC 
SYNDROMES
Many PNS of different origin show some hemato-
logic manifestation. They include the following.
Erythrocytosis is mostly associated with renal 
cell carcinoma. The elevated serum erythropoietin 
is the chief reason of this PNS. Hepatoma is the next 
most common malignancy leading to erythrocytosis. 
The elevation of serum erythropoietin is also the rea-
son of the development of erythrocytosis. Other 
tumors may be also accompanied by erythrocytosis. 
They include the following neoplasms: Wilms’ tumor, 
he mangiomas, cerebellar hemangioblastoma, sarco-
mas, uterine fibrosis, and adrenal tumors [18].
There are obvious cases of polycythemia con-
nected with arterial desaturation associated with 
hemoglobinopathies, carboxyhemoglobinemia, and 
chronic hypoxic states [19].
The anemias are typical for many kinds of tumors, 
especially at advanced stages. They are normo-
cytic normochromic or hypochromic, connected with 
chronic diseases, with bone marrow invasion, se-
condary to cytostatic therapy and radiation treatment. 
Normochromic normocytic anemia in cancer patients 
is a common PNS.
Paraneoplastic anemia is characterized by low 
serum iron levels, normal or increased ferritin levels, 
normal iron stores, and low serum erythropoietin level. 
Pure red cell aplasia is a rare cause of anemia in cancer 
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patients. It can be associated with thymoma and hy-
pogammaglobulinemia. This PNS may also be associ-
ated with different lymphoid malignancies. It is rarely 
caused by solid tumors. Warm antibody hemolytic 
anemia is most commonly associated with lympho-
mas. Cold agglutinin disease is most connected with 
Waldenström’s macroglobulinemia and lymphomas. 
Autoimmune hemolytic anemia may be associated 
with solid tumors, such as ovarian, lung, breast, gas-
trointestinal and renal cancers.
DIC can follow the microangiopathic hemolytic 
anemia in metastatic carcinomas [20].
As a PNS, microangiopathic hemolytic anemia may 
respond to effective anticancer therapy. The mecha-
nism of most PN anemias remains unknown.
Granulocytosis with elevation of white blood 
cell count without infection or leukemia is common 
in neoplasms as one of the PNS. Usually, tumors that 
are accompanied by granulocytosis include Hodg-
kin’s lymphoma, different other lymphomas, and a va-
riety of solid tumors such as stomach, lung, pancreatic, 
brain cancers, and malignant melanoma. The common 
mechanism associated with granulocytosis is produc-
tion of growth factors by the tumor.
Granulocytopenia may appeare as a PNS. Except 
under the influence of chemotherapy, radiation therapy 
or tumor infiltration of bone marrow, the tumors can 
rarely produce a factor that would suppress granu-
lopoieses by interfering with many growth factors. 
There are several reports about antibodies against 
granulocytes in patients with Hodgkin’s lymphoma. 
Neutropenia associated with large granular lympho-
cytic leukemia and lymphoma may be caused by im-
mune dysregulation of T-cells.
In some cases, thrombophlebitis represents 
an incident of PNS. Oncological patients have a hy-
percoagulable state. An association between venous 
thrombosis and malignancy was first suggested 
by Trousseau in 1865. Clinical thromboembolism 
occurs in 11% of cancer patients and is the second 
leading cause of death in patients with overt malig-
nant diseases. Clearly, cancer related thrombosis has 
a complex of features including different imbalances 
of coagulation and fibrinolysis. Several studies of pa-
tients with venous thromboembolism suggest a higher 
incidence of malignancy diagnosed within the first 
6 months after presentation of thrombosis.
Several paraneoplastic coagulopathies associated 
with cancer have been reported too. It concerns such 
localizations of malignancy as gastric and adrenal 
carcinomas, leukemias and lymphomas [2, 21].
Acquired hemophilia (factor VIII antibodies) has 
been reported in patients with solid tumors, parapro-
teinemias and lymphoproliferative disorders. Overt DIC 
occurs in 7% of patients with solid tumors (primarily 
adenocarcinomas). Eosinophilia, basophilia, thrombo-
cytosis, thrombocytopenia, and thrombophlebitis also 
belong to hematologic manifestations of PNS [22].
Hematologic manifestations of cancer include 
also nonbacterial thrombotic endocarditis. It may lead 
to thrombotic or hemorrhagic complications and may 
occur with or without DIC. Nonbacterial endocarditis 
should be suspected in cancer patients with ischemic 
embolic events and is most commonly seen with 
adenocarcinomas of the lung and pancreas [20, 21].
PARANEOPLASTIC RENAL SYNDROMES
Renal manifestations often accompany several 
kinds of malignancy. In 22% of cases membranous 
nephropathy has been clearly associated with a malig-
nancy. Most common malignancies in this connection 
are lung, colon, and stomach carcinomas.
Nephrosis-ranged proteinuria, hypertension 
and microscopic hematuria characterize the syn-
drome. Immune complexes are thought to play a role 
in malignancy-associated glomerular disease. The re-
sponsible antigens include fetal antigens, autologous 
nontumor antigens, tumor-associated antigens, and 
viral antigens [4].
Other glomerular diseases include membrano-
proliferative glomerulonephritis and minimal-change 
di sease. Hodgkin’s lymphoma is the cause of most 
cases of minimal-change disease with lympho-
proliferative disorders, pancreatic carcinoma, and 
mesothelioma. Approximately 10–15% of cases 
precede the lymphoma and 40–50% manifest after 
the tumor is diagnosed. There is a parallel relationship 
between the activity of the lymphoma and the degree 
of proteinuria.
Other cancer-associated glomerulopathies in-
clude focal and segmental glomerulosclerosis with 
CLL, T-cell non-Hodgkin’s lymphomas, and acute 
myelo genous leukemia. Immunoglobulin A nephropa-
thy is associated with lung, head, and neck cancer, 
pancreatic cancer, mycosis fungoides, and liposar-
coma. Membranoproliferative glomerulonephritis 
is con nected with chronic lymphoblastic leukemia, 
Burkitt’s and other lymphomas, hairy cell leukemia, 
and malignant melanoma [3].
Thus, the nephrologists have to do with different 
PNS that need to be differentiated from non-oncologi-
cal renal diseases and vice versa. Internists encounter 
the PNS more often than other specialists. In internal 
medicine clinics classic PNS is encountered in 90% 
of patients with PNS, the endocrine and metabolic syn-
dromes in 7–10%, the rheumatoid-like — in 25–62%, 
the cardiovascular — in up to 50%, dermatological — 
in 14–63%, neurological — in 1%, gastrointestinal 
syndromes — in 12–22%, hematological — in 35–55% 
of patients. Consequently, the internists have to re-
member about the possibility of PNS in their patients.
PARANEOPLASTIC RHEUMATOLOGIC 
SYNDROMES
Rheumatologists are of special importance among 
other representatives of medical professions. In their 
practice, rheumatologists often encounter the so-
called “masks” — typical for rheumatological disorders 
but sometimes present as a part of PNS.
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Rheumatologic diseases and malignancies have 
many common features — in ethiology, diagnostics, 
and complications, including some PNS.
The peculiarities of paraneoplastic rheumatic syn-
dromes are as follows:
• chronological correlation with oncological dise-
ases;
• frequent occurrence in elderly age;
• asymmetric affection of joints;
• predominant involvement of lower limbs into 
the process;
• abrupt in onset;
• as a rule, absence of rheumatoid factors and rheu-
matoid nods;
• nonspecific alterations in synovial bioptates;
• positive dynamics of PNS during the successful 
treatment of malignancy;
• “rheumatological” symptoms recurrence caused 
by metastases or local recurrence of the malig-
nancy.
Rheumatologic PNS include:
• hyperytrophic osteoarthropathy (Marie — Bam-
berger syndrome);
• rheumatoid arthritis;
• dermatomyositis;
• tendovaginitis migricans;
• scleroderma-like syndrome;
• different types of vasculitis including panarteritis 
nodosa and Wegener’s vasculitis;
• lupus erythematosus;
• palmar hyperkeratosis;
• polychondritis and many other above-mentioned 
syndromes [2–4].
Malignization is often accompanied by autoimmune 
processes that are followed by production of a variety 
(nearly 400 kinds) of antibodies against the bright spec-
trum of antigens. Oncoproteins controlling the cellular 
growth and differentiation are best known among them. 
For example, 50% of patients with breast cancer repre-
sent p185, some other proteins are associated with lung 
cancer, ovaries and colon malignancies. Best known 
is p53 which prevents cancerogenese and teratogenous 
disorders. In the process of mutation, it loses the named 
properties and is present in many tumors in such form. 
Its specificity is nearly 96%, so it can serve as a test for 
early diagnosis in high-risk patients. The antigens con-
nected with cell proliferation are present in every kind 
of cancer in 2% of cases.
It is known that autoimmune rheumatological disor-
ders are connected with a lot of antibodies — Ro, La, 
Sm, RNP, and others may be present in patients with 
malignancies. A high level (22%) of antiphospholipid 
antibodies (aPL) is detected in 3% of patients with 
malignancies as compared to healthy contingent. 
The risk of thrombosis triples in oncologic patients with 
aPL(+) in comparison with the patients with aPL(−). 
At the same time, a patient with aPL(+) has a higher 
risk of cancer development.
The so-called classic PNS which include fever, 
asthenia, cachexia, and anaemia are worth discussing. 
These signs are common for a large number of ma-
lignancies and some researchers argue that these 
symptoms characterize tumorous intoxication.
PNS simulating autoimmune disorders are quite 
frequent in rheumatological practice. Relation between 
tumors and autoimmune processes is rather compli-
cated. Many factors take place in those relations.
An allergic reaction often develops on the back-
ground of tumors.
Oncoantigens further sensitize the organism. This 
leads to violation of immunologic tolerance to autoan-
tigens. Anticancer drugs also have influence on the im-
munological state of the organism. As a result, many 
rheumatological signs appear also in cancer patients.
Emergence and development of tumors is ac-
companied by metabolic changes in the organism 
that lead to disturbance of protein, fat, carbohydrate 
metabolism, and to infringement of immune system. 
Clinical signs of such events include weakness, tired-
ness, hypodynamia, disturbance of sleep, weight loss, 
hypothermia, and several other symptoms. These 
facts are defined as endogen intoxication syndrome 
or tumor toxicosis. These phenomena are present 
in 70–80% of oncological patients [23].
To compare PNS it is necessary to remember that 
the same signs can be evaluated as common symp-
toms of many PNS.
Reports on sorbtion appeared in oncological litera-
ture at the end of the previous century [24].
Rheumatoid arthritis or asymmetric polyarthritis 
may occur with malignancy.
Joint manifestations regress on removal or control 
of the underlying malignancy in 48% of patients. About 
80% of female patients with asymmetric polyarthritis 
and malignancy had breast cancer. Some 83% of pa-
tients with polymyalgia rheumatica are said to develop 
a malignancy within 3 months and some of these cases 
may represent arterial embolism of muscle through 
nonbacterial thrombotic endocarditis. Lymphomas 
may be associated with systemic rheumatic disease. 
In Sjögren’s syndrome a spectrum of benign to ma-
lignant lymphoproliferations can be seen, but whether 
this is “at a distance from the tumor” remains to be de-
termined [29].
Metastases to joints can simulate rheumatoid ar-
thritis and cytological examinations should be done 
in regard to joint effusions in cancer patients [30].
Fever occurs frequently in cancer patients and 
is usually caused by infection. In addition, there 
 exist other noninfectious causes, with which certain 
concerns are associated. Main associations are with 
Hodgkin’s lymphoma, myxomas, hypernephromas, 
osteogenic sarcomas, and other tumors. Tumor-
associated fever is usually defined as “unexplained” 
fever that coincides with tumor growth, disappears 
promptly on tumor removal or control and reappears 
with tumor recurrence. When the fever persists, the tu-
mor is a likely cause of it if other reasonable causes 
are excluded. In Hodgkin’s disease, fever is a bad 
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prognostic sign. There are no data on the influence 
of fever associated with other tumors on prognosis.
The etiology of tumor-associated fever is con-
nected with several “endogenous” pyrogens released 
by tumor cells [25, 26].
Some malignant cells are able to stimulate 
the production of “blocking antibodies” against 
tumor antigens, for example, the production of im-
munoglobulins of A, E, and D classes which do not 
activate the complement system and conjugates with 
tumoro us antigens building antigen-antibodies com-
plex on the surface of cancer cell which can cause 
the so-called immune-complex syndrome similar 
to PNS or tumor toxicosis [32].
All of these pathologies are characterized by an ag-
gregate of symptoms including weakness, tiredness, 
hypodynamia, sleep disorders, appetite loss, paleness, 
hypothermia, and other symptoms. Some decades ago 
such complexes of metabolic and nonspecific clinical 
signs were evaluated as tumor toxicosis and a corre-
sponding treatment was proposed [33]. We investigated 
the possibilities of detoxication treatment, including 
hemosorption, lymphosorption, enterosorption, and 
others. We learned that in some cases not only does 
the sorption treatment give unexpectedly positive re-
sults in regard to clinical course but sometimes also 
facilitates the reduction of the tumor [34].
In particular, plasmapheresis was used in 4 patients 
with lung cancer, and provided for lessening or even 
elimination of clinical symptoms influencing clini-
cal, biochemical and immunological manifestations 
of intoxications, and giving the possibility to finish 
the course of radio- of chemotherapy [35]. Another 
study showed positive subjective changes of the pa-
tients’ condition, lower concentrations of circulating 
immune complexes and improvement of reactions 
of cell-mediated immunity (blast-transformation re-
action and E-rosetting cell) in patients with extended 
forms of tumor process after use of hemosorption [36].
Taking into account the previous clinical experience 
we can state that the so-called tumorous toxicosis 
is a part of PNS and it is reasonable to discuss the idea 
of detoxication from the present-day perspective.
Analyzing the problem of PNS and the attitude of dif-
ferent medical professionals to it, we can claim that in-
ternists, dermatologists, rheumatologists, neurologists, 
and other non-oncology professionals encounter PNS 
in their everyday medical practice. For these specialists 
the presence of the abovementioned syndromes may 
be a display of usual diseases (like rheumatism, skin 
diseases, kidney failure, etc.) that needs a specific treat-
ment. In the case when the disease is not connected 
with the mentioned conditions but is a manifestation 
of malignancy (PNS) the treatment of a non-oncological 
disease leads to the loss of time with corresponding 
consequences. That is why the correct differential 
diagnosis is very important for the mentioned experts.
The subject of PNS is not sufficiently covered 
in special oncology literature, the reason of which 
lies in the fact that oncologists having a morphologi-
cal confirmation of malignancy interpret all present 
symptoms as a manifestation of cancer.
According to estimations, PNS does not correlate 
with the stage of tumor or its prognosis. That is why 
they stay outside the consideration of oncologists.
The problem of tumor toxicosis (or immune-
complex disease corresponding to malignancies) was 
discussed in special literature several decades ago. 
As a logical conclusion, a detoxication or deblocking 
treatment was proposed. Probably it could be rea-
sonable to return to this idea in some patients with PNS.
CONCLUSIONS
1. PNS are a heterogenous group of phenomena 
caused by malignancies influencing the endocrine and 
immune systems, metabolism, and other mechanisms, 
not all of which have been identified by now.
2. Not all facts that are described as PNS cor-
respond to the identification criteria for PNS. Some 
of them are not influenced by radical treatment 
of the tumor, whereas such influence is postulated 
as obligatory for PNS cases.
3. Some PNS are life-threatening and therefore 
require active treatment.
4. Tumorous toxicosis or immune-complex dise-
ase, which were widely discussed in the past decades, 
are de facto a part of PNS and consequently their 
respective treatment deserves attention.
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